Comparative assessment of the absorption of a generic formulation of dimethyl fumarate capsule against the innovator dimethyl fumarate capsule conducted under fasting condition in healthy male and female volunteers.
A single dose, randomized, blinded, pilot study of a test formulation of dimethyl fumarate capsule in a 2 way crossover comparison against the innovator dimethyl fumarate capsule conducted under fasting conditions in healthy male and female volunteers.
Zenith Technology Corporation Limited
12 participants
May 3, 2019
Interventional
Conditions
Summary
The objective of this pilot study is to evaluate the bioequivalence of the test formulation relative to the that of a reference formulation, following oral administration of a combination single dose of 240 mg dimethyl fumarate capsule to healthy male and female subjects under fasting conditions.
Eligibility
Inclusion Criteria6
- Healthy males and non-pregnant female volunteers.
- Aged between 18 and 55
- Non-smoker
- BMI between 18.5 and 32
- Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- Able to provide written informed consent
Exclusion Criteria9
- Concomitant drug therapy of any kind
- Any clinically significant medical conditions
- Sensitive to the study drug
- History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- Females who are pregnant and/or breastfeeding
- Smoker (anyone who has smoked in the last 6 months)
- History of alcohol or drug abuse or dependency
- Participation in a drug study within 60 days of the start of the study or donated blood within the 60 days preceding the study
- Volunteers for whom the Clinical Investigator believer, for any reason, that participation would not be an acceptable risk
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose, crossover study design whereby each participant receives the test formulation of 240 mg dimethyl fumarate capsule on one occasion and the innovator formulation of 240 mg dimethyl fumarate capsule on one occasion with each dose separated by a one week washout period. The intervention for this trial is the test capsule formulation. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for water consumed with the dose). Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing. Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing. Each dose ( 1 x 204 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12619000576123